Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 41 studies | 44% ± 22% | |
endothelial cell | 24 studies | 44% ± 20% | |
endothelial cell of lymphatic vessel | 22 studies | 57% ± 24% | |
smooth muscle cell | 17 studies | 28% ± 14% | |
endothelial cell of vascular tree | 13 studies | 42% ± 18% | |
vein endothelial cell | 12 studies | 47% ± 22% | |
pericyte | 11 studies | 38% ± 17% | |
connective tissue cell | 10 studies | 47% ± 15% | |
adipocyte | 10 studies | 43% ± 11% | |
endothelial cell of artery | 9 studies | 38% ± 14% | |
type II pneumocyte | 8 studies | 36% ± 14% | |
mesothelial cell | 8 studies | 45% ± 28% | |
myofibroblast cell | 7 studies | 42% ± 19% | |
hepatocyte | 6 studies | 65% ± 29% | |
adventitial cell | 5 studies | 72% ± 20% | |
basal cell | 4 studies | 38% ± 20% | |
capillary endothelial cell | 4 studies | 32% ± 19% | |
hepatic stellate cell | 3 studies | 44% ± 19% | |
abnormal cell | 3 studies | 56% ± 26% | |
glial cell | 3 studies | 43% ± 22% | |
epithelial cell | 3 studies | 61% ± 31% | |
luminal hormone-sensing cell of mammary gland | 3 studies | 22% ± 4% | |
endothelial cell of sinusoid | 3 studies | 27% ± 10% | |
muscle cell | 3 studies | 47% ± 15% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 98% | 20281.96 | 449 / 459 | 87% | 124.67 | 970 / 1118 |
lung | 95% | 12130.69 | 551 / 578 | 82% | 143.23 | 951 / 1155 |
liver | 97% | 60740.88 | 219 / 226 | 75% | 424.73 | 306 / 406 |
skin | 83% | 14736.75 | 1493 / 1809 | 57% | 82.36 | 269 / 472 |
kidney | 52% | 5204.29 | 46 / 89 | 85% | 717.85 | 767 / 901 |
bladder | 67% | 8877.95 | 14 / 21 | 53% | 96.41 | 266 / 504 |
uterus | 65% | 5029.36 | 111 / 170 | 54% | 115.70 | 248 / 459 |
intestine | 66% | 5779.03 | 642 / 966 | 41% | 53.43 | 214 / 527 |
pancreas | 14% | 655.63 | 45 / 328 | 92% | 291.94 | 163 / 178 |
adipose | 100% | 25000.50 | 1203 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 25745.14 | 1332 / 1335 | 0% | 0 | 0 / 0 |
ovary | 38% | 2337.13 | 69 / 180 | 60% | 94.02 | 257 / 430 |
esophagus | 54% | 4131.24 | 787 / 1445 | 42% | 44.33 | 77 / 183 |
thymus | 77% | 6346.49 | 504 / 653 | 19% | 16.48 | 117 / 605 |
stomach | 46% | 4461.81 | 165 / 359 | 48% | 49.41 | 137 / 286 |
spleen | 89% | 6474.22 | 215 / 241 | 0% | 0 | 0 / 0 |
prostate | 51% | 4322.06 | 124 / 245 | 31% | 27.83 | 158 / 502 |
muscle | 67% | 13936.64 | 542 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 55% | 71.28 | 16 / 29 |
heart | 45% | 3068.41 | 385 / 861 | 0% | 0 | 0 / 0 |
adrenal gland | 22% | 998.19 | 57 / 258 | 11% | 19.33 | 26 / 230 |
tonsil | 0% | 0 | 0 / 0 | 31% | 28.50 | 14 / 45 |
brain | 0% | 4.39 | 3 / 2642 | 22% | 49.41 | 152 / 705 |
peripheral blood | 1% | 137.10 | 13 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0090312 | Biological process | positive regulation of protein deacetylation |
GO_0045722 | Biological process | positive regulation of gluconeogenesis |
GO_0006769 | Biological process | nicotinamide metabolic process |
GO_0009410 | Biological process | response to xenobiotic stimulus |
GO_0031100 | Biological process | animal organ regeneration |
GO_0032259 | Biological process | methylation |
GO_0034356 | Biological process | NAD biosynthesis via nicotinamide riboside salvage pathway |
GO_0010243 | Biological process | response to organonitrogen compound |
GO_0005829 | Cellular component | cytosol |
GO_0030760 | Molecular function | pyridine N-methyltransferase activity |
GO_0008112 | Molecular function | nicotinamide N-methyltransferase activity |
Gene name | NNMT |
Protein name | NNMT protein (Nicotinamide N-methyltransferase) Nicotinamide N-methyltransferase (EC 2.1.1.1) |
Synonyms | hCG_39357 |
Description | FUNCTION: Catalyzes the N-methylation of nicotinamide using the universal methyl donor S-adenosyl-L-methionine to form N1-methylnicotinamide and S-adenosyl-L-homocysteine, a predominant nicotinamide/vitamin B3 clearance pathway . Plays a central role in regulating cellular methylation potential, by consuming S-adenosyl-L-methionine and limiting its availability for other methyltransferases. Actively mediates genome-wide epigenetic and transcriptional changes through hypomethylation of repressive chromatin marks, such as H3K27me3 . In a developmental context, contributes to low levels of the repressive histone marks that characterize pluripotent embryonic stem cell pre-implantation state . Acts as a metabolic regulator primarily on white adipose tissue energy expenditure as well as hepatic gluconeogenesis and cholesterol biosynthesis. In white adipocytes, regulates polyamine flux by consuming S-adenosyl-L-methionine which provides for propylamine group in polyamine biosynthesis, whereas by consuming nicotinamide controls NAD(+) levels through the salvage pathway (By similarity). Via its product N1-methylnicotinamide regulates protein acetylation in hepatocytes, by repressing the ubiquitination and increasing the stability of SIRT1 deacetylase (By similarity). Can also N-methylate other pyridines structurally related to nicotinamide and play a role in xenobiotic detoxification . . |
Accessions | P40261 ENST00000535401.5 ENST00000299964.4 B0YJ53 |